Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Bioxcel therapeutics, inc. save search
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 13.74%
H: 2.08%
C: -18.75%
bxcl701 fda cancer cell treatment designation therapeutics
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 3.88%
H: 3.11%
C: -0.62%
bxcl501 opioid update treatment trial therapeutics potential
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
Published: 2023-06-29 (Crawled : 10:00) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -51.1%
H: 9.49%
C: -26.04%
bxcl501 alzheimer’s positive treatment topline trial therapeutics results
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia
Published: 2023-05-25 (Crawled : 11:00) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -0.04%
H: 1.16%
C: -25.46%
bxcl501 treatment topline schizophrenia results
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-12-19 (Crawled : 12:20) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 1.0%
H: 0.67%
C: -1.23%
treatment disease trial therapeutics alzheimer’s
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
Published: 2022-11-30 (Crawled : 13:00) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 1.05%
H: 8.6%
C: 8.02%
treatment schizophrenia trial therapeutics
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 4.1%
H: 1.65%
C: 1.01%
treatment disease trial therapeutics alzheimer’s phase 3 alzheimer's
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
Published: 2022-04-06 (Crawled : 12:20) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 9.41%
H: 12.97%
C: -8.6%
treatment fda schizophrenia approval therapeutics
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2021-12-15 (Crawled : 12:30) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -3.82%
H: 8.09%
C: 7.79%
bxcl501 alzheimer treatment therapeutics disease cel phase 3 alzheimer’s alzheimer's disease alzheimer's
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
Published: 2021-12-01 (Crawled : 12:30) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -13.2%
H: 11.23%
C: 8.21%
treatment fda schizophrenia order therapeutics
BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 0.15%
H: 6.75%
C: 3.39%
treatment phase 2 prostate cancer expansion endocrine cancer trial merge
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
Published: 2021-05-19 (Crawled : 12:00) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 0.79%
H: 1.84%
C: -1.59%
treatment fda fda acceptance schizophrenia
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia
Published: 2021-03-15 (Crawled : 12:00) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 5.93%
H: 0.01%
C: -2.14%
treatment fda dementia therapy breakthrough therapy designation
BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of Agitation
Published: 2021-03-11 (Crawled : 14:00) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 5.44%
H: 1.8%
C: -1.07%
new drug food treatment drug application
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation
Published: 2021-03-03 (Crawled : 12:03) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 1.2%
H: 0.37%
C: -11.47%
treatment dementia program
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related AgitationTopline results are expected in Q1 2022
Published: 2021-02-25 (Crawled : 19:00) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 0.84%
H: 5.05%
C: -4.02%
treatment phase 2 results trial
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation
Published: 2021-02-25 (Crawled : 12:03) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 0.84%
H: 5.05%
C: -4.02%
treatment phase 2 trial
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET
Published: 2021-02-12 (Crawled : 13:00) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 0.0%
H: 1.75%
C: -6.04%
treatment opioid potential
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
Published: 2021-02-12 (Crawled : 12:03) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 0.0%
H: 1.75%
C: -6.04%
treatment opioid potential
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
Published: 2021-01-05 (Crawled : 12:03) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -0.48%
H: 1.35%
C: -8.19%
disease alzheimer dementia phase 1b alzheimer’s alzheimer's disease alzheimer's phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.